3/23/2005

Pennsylvania-based Demegen said it licensed certain peptides to Pacgen Biopharmaceuticals, a Vancouver, British Columbia, firm specializing in drug design and development for infectious diseases and immune system regulations. Pacgen's CEO said the move would help his firm move products to the market more quickly.

Related Summaries